UP!

ADHD $1.46   View long term graphs

Alcobra Ltd.
Type
Public company
Traded as NASDAQ: ADHD
Industry Pharmaceutical industry
Headquarters Tel Aviv, Israel
Products Metadoxine Extended Release; MDX
Website www.alcobra-pharma.com

Alcobra Ltd. is a public, specialty pharmaceutical company. The company is focused on the development of new medications to help patients with cognitive disorders, including attention deficit hyperactivity disorder (ADHD) and fragile X syndrome.

Alcobra is headquartered in Tel Aviv, Israel, and also has a U.S. office located outside of Philadelphia in Plymouth Meeting, Pennsylvania.

Alcobra was founded in 2008. In 2013, the company completed an initial public offering (IPO) and trades under the symbol “ADHD” on the NASDAQ stock exchange.

Metadoxine Extended Release (MDX) is the company’s lead investigational product candidate. Metadoxine Extended Release is a monoamine-independent modulator of GABA (gamma-aminobutyric acid) transmission. The mechanism of action does not directly affect dopamine or norepinephrine. The compound is not a psychostimulant. Metadoxine has shown no potential for abuse or addiction in studies completed to date.

Alcobra has completed two Phase II trials and one Phase III trial of Metadoxine Extended Release (MDX) in adults with ADHD. Alcobra has also completed one Phase II adolescent ADHD study of Metadoxine Extended Release (MDX). In mid-2015, Alcobra began a second Phase III trial of Metadoxine Extended Release (MDX) in adults with ADHD, called the MEASURE study.

In December 2013, the FDA granted "Orphan Drug" designation to Metadoxine in the treatment of fragile X syndrome. In June 2015, Alcobra completed a Phase II clinical trial of MDX for the treatment of adolescents and adults with fragile X syndrome. In September 2015, the FDA granted “Fast Track” status to Metadoxine Extended Release (MDX) for fragile X syndrome.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2018 2018-05-17 Future report Set alerts
Q4 2017 2018-02-28 Future report Set alerts
Q3 2017 2017-11-09 -0.10 0.00
Q2 2017 2017-08-11 -0.13 -0.13
Q1 2017 2017-05-30 -0.13 -0.13
Q4 2016 2017-02-15 -0.22 -0.22
Q3 2016 2016-11-15 -0.28 -0.28
Q2 2016 2016-08-30 -0.21 -0.21
Q1 2016 2016-05-16 -0.18 -0.18
Q4 2015 2016-02-17 -0.20 -0.20

Ratings

2016-06-21 Reiterated Rating Roth Capital Buy $12.00
2016-06-07 Initiated Coverage Cantor Fitzgerald Buy $16.00
2016-06-07 Initiated Coverage Canaccord Genuity Buy
2016-02-18 Initiated Coverage Jefferies Group Buy $10.00
2016-02-18 Initiated Coverage Jefferies Buy $10.00
2016-02-04 Initiated Coverage Roth Capital Buy $15.00
2016-01-25 Initiated Coverage Oppenheimer Outperform $16.00
2016-01-25 Initiated Coverage Oppenheimer Holdings Inc. Outperform $16.00
2015-08-14 Boost Price Target Roth Capital Buy $10.00 to $16.00
2015-08-09 Reiterated Rating WBB Securities Hold $5.00
2015-06-24 Set Price Target Piper Jaffray Buy $21.00
2015-06-24 Downgrade WBB Securities Speculative Buy to Hold $5.00
2015-06-24 Set Price Target Piper Jaffray Cos. Buy $21.00
2015-02-23 Initiated Coverage Roth Capital Buy $10.00
2015-02-10 Initiated Coverage Roth Capital Buy $10.00
2014-11-18 Lower Price Target Roth Capital Buy $30.00 to $10.00
2014-11-17 Downgrade Aegis Buy to Hold
2014-10-23 Downgrade FBR Capital Outperform to Mkt Perform $22 to $4
2014-10-23 Downgrade FBR & Co. Outperform to Market Perform $22.00 to $4.00
2014-10-23 Reiterated Rating Aegis Buy
2014-10-23 Downgrade Piper Jaffray Overweight
2014-10-23 Downgrade FBR & Co Outperform to Market Perform $22.00 to $4.00
2014-10-07 Upgrade WBB Securities Hold to Speculative Buy $18 to $9
2014-10-07 Downgrade Canaccord Genuity Buy to Hold $40.00 to $9.00
2014-10-07 Upgrade FBR & Co. Market Perform to Outperform $23.00 to $22.00
2014-10-06 Reiterated ROTH Capital Buy $40 to $30
2014-10-06 Lower Price Target Roth Capital Buy $40.00 to $30.00
2014-10-06 Reiterated Rating ING Group Buy
2014-08-27 Initiated FBR Capital Mkt Perform $23
2014-08-27 Initiated Coverage FBR & Co. Market Perform $23.00
2014-08-04 Initiated Coverage Piper Jaffray Overweight $42.00
2014-08-01 Initiated Coverage Roth Capital Buy $40.00
2014-06-26 Initiated Coverage WBB Securities Hold $18.00
2014-05-16 Boost Price Target Canaccord Genuity $24.00 to $40.00
2014-04-17 Initiated Coverage Canaccord Genuity Buy $24.00
2014-03-06 Initiated Coverage JMP Securities Outperform $36.00
2014-01-02 Reiterated Rating Aegis Top Pick
2013-12-04 Initiated Stifel Buy $27
2013-12-04 Initiated Coverage Stifel Nicolaus Buy $27.00
2013-10-08 Reiterated Aegis Capital Buy $30 to $40
2013-10-08 Boost Price Target Aegis Buy $30.00 to $40.00
2013-07-08 Initiated Aegis Capital Buy $30
2016-06-21 Reiterated Rating Roth Capital Buy $12.00
2016-06-07 Initiated Coverage Cantor Fitzgerald Buy $16.00
2016-06-07 Initiated Coverage Canaccord Genuity Buy
2016-02-18 Initiated Coverage Jefferies Group Buy $10.00
2016-02-18 Initiated Coverage Jefferies Buy $10.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ADHD 3 funds of 2183 total. Show all

Fund name Ticker shares
VHCP Management, LLC 0.66M
Nine Chapters Capital Management LLC 13000
MetLife Securities, Inc 840

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments